Compare ADUS & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | MNKD |
|---|---|---|
| Founded | 1979 | 1991 |
| Country | United States | United States |
| Employees | N/A | 592 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 793.6M |
| IPO Year | 2009 | 2004 |
| Metric | ADUS | MNKD |
|---|---|---|
| Price | $94.48 | $2.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $135.40 | $8.64 |
| AVG Volume (30 Days) | 204.3K | ★ 4.8M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.40 | N/A |
| EPS | ★ 5.22 | 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $9.17 | $35.81 |
| Revenue Next Year | $4.64 | $11.89 |
| P/E Ratio | ★ $17.66 | $128.25 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $90.89 | $2.23 |
| 52 Week High | $124.44 | $6.51 |
| Indicator | ADUS | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 39.85 |
| Support Level | N/A | $2.52 |
| Resistance Level | $118.51 | $6.18 |
| Average True Range (ATR) | 2.97 | 0.13 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 37.51 | 88.89 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.